DAM
ESPR

Deltec Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Deltec Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$796K Buy
+252,050
New +$705K 0.12% 121

Other funds holding ESPR

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Deltec Asset Management's ESPR Position: Q2 2026 in Review

Deltec Asset Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 252,050 shares worth $796K. The stake represents 0.12% of the portfolio and ranks #121 among its holdings.

27 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Deltec Asset Management held 252,050 shares of Esperion Therapeutics worth $796K as of Q2 2026.
  • Esperion Therapeutics was a new Deltec Asset Management position in Q2 2026.
  • Esperion Therapeutics made up 0.12% of Deltec Asset Management's portfolio in Q2 2026, its #121 holding.
  • 27 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Deltec Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.